Background:To find the changes of macular perimetry(MP) and the correlations between MP and best correct visual acuity(BCVA) in different phases of the acute central serous chorioretinopathy(CSC).Methods:Twenty-one ey...Background:To find the changes of macular perimetry(MP) and the correlations between MP and best correct visual acuity(BCVA) in different phases of the acute central serous chorioretinopathy(CSC).Methods:Twenty-one eyes with acute CSC and their fellow eyes were analysed retrospectively.MP at 2°,4°and BCVA in the active and resolved phase were collected and analyzed.The differences of these parameters in CSC eyes and fellow eyes were analyzed.Spearman correlation was used for analysis of correlation between MP and BCVA.Results:From 29 eyes with CSC analysed 27 eyes(93.10%) recovered to the previous VA.Compared with the active phase,MP at 2°,4° and BCVA were significantly improved in the resolved phase(P=0.000,0.000,0.000,respectively).MP at 2°,4° and BCVA of CSC eyes were significantly poor compared with the fellow eyes in the active phase(P=0.000,0.000,0.000,respectively).In the resolved phase there was no significant difference between the CSC eyes and fellow eyes(P=0.339,0.141,0.161,respectively).BCVA was shown to significantly correlate with MP at 2° in the active phase(ρ=-0.630,P<0.001).Conclusions:The acute CSC often had a good prognosis both in BCVA and MP.MP can provide an additional objective parameter to evaluate the retinal function changes at macula of acute CSC.展开更多
Purpose: To study the safety and efficacy of 1/3-dose verteporfin photodynamic therapy (PDT) for subacute central serous chorioretinopathy (CSC). Methods: In this case series, 59 eyes (59 patients) diagnosed with suba...Purpose: To study the safety and efficacy of 1/3-dose verteporfin photodynamic therapy (PDT) for subacute central serous chorioretinopathy (CSC). Methods: In this case series, 59 eyes (59 patients) diagnosed with subacute CSC in Shenyang the 4th hospital from January 2014 to December 2015 were treated with 1/3-dose verteporfin PDT and followed up for at least 1 year. The symptoms and the diagnosed history were more than 3 months but shorter than 6 months. The central foveal thickness (CFT), neuroretinal thickness (NRT), height of subfoveal retinal fluid (SRF), and subfoveal choroidal thickness (SCT) were observed at baseline and after treated at 1, 2, 3, 6 and 12 months with EDI-OCT, Best-corrected visual acuity ( BCVA) was also studied at the same time. Results: After 1, 2, 3 and 6 months of 1/3-dose verteporfin PDT treatment, the BCVA improved significantly (P 0.05). The height of SRF changed significantly. There was no retinal pigment epithelium atrophy and choroidal neovascularization (CNV) in all cases after more than 12 months follow-up. Conclusion: Treatment of 1/3 dose verteporfin PDT could safely and effectively reduce expansion of choroidal vessel and choroidal choriocapillary, promoting absorbance of subretinal fluid for subacute CSC. 1/3-dose verteporfin PDT may be an alternative method to treat the subacute CSC.展开更多
文摘Background:To find the changes of macular perimetry(MP) and the correlations between MP and best correct visual acuity(BCVA) in different phases of the acute central serous chorioretinopathy(CSC).Methods:Twenty-one eyes with acute CSC and their fellow eyes were analysed retrospectively.MP at 2°,4°and BCVA in the active and resolved phase were collected and analyzed.The differences of these parameters in CSC eyes and fellow eyes were analyzed.Spearman correlation was used for analysis of correlation between MP and BCVA.Results:From 29 eyes with CSC analysed 27 eyes(93.10%) recovered to the previous VA.Compared with the active phase,MP at 2°,4° and BCVA were significantly improved in the resolved phase(P=0.000,0.000,0.000,respectively).MP at 2°,4° and BCVA of CSC eyes were significantly poor compared with the fellow eyes in the active phase(P=0.000,0.000,0.000,respectively).In the resolved phase there was no significant difference between the CSC eyes and fellow eyes(P=0.339,0.141,0.161,respectively).BCVA was shown to significantly correlate with MP at 2° in the active phase(ρ=-0.630,P<0.001).Conclusions:The acute CSC often had a good prognosis both in BCVA and MP.MP can provide an additional objective parameter to evaluate the retinal function changes at macula of acute CSC.
文摘Purpose: To study the safety and efficacy of 1/3-dose verteporfin photodynamic therapy (PDT) for subacute central serous chorioretinopathy (CSC). Methods: In this case series, 59 eyes (59 patients) diagnosed with subacute CSC in Shenyang the 4th hospital from January 2014 to December 2015 were treated with 1/3-dose verteporfin PDT and followed up for at least 1 year. The symptoms and the diagnosed history were more than 3 months but shorter than 6 months. The central foveal thickness (CFT), neuroretinal thickness (NRT), height of subfoveal retinal fluid (SRF), and subfoveal choroidal thickness (SCT) were observed at baseline and after treated at 1, 2, 3, 6 and 12 months with EDI-OCT, Best-corrected visual acuity ( BCVA) was also studied at the same time. Results: After 1, 2, 3 and 6 months of 1/3-dose verteporfin PDT treatment, the BCVA improved significantly (P 0.05). The height of SRF changed significantly. There was no retinal pigment epithelium atrophy and choroidal neovascularization (CNV) in all cases after more than 12 months follow-up. Conclusion: Treatment of 1/3 dose verteporfin PDT could safely and effectively reduce expansion of choroidal vessel and choroidal choriocapillary, promoting absorbance of subretinal fluid for subacute CSC. 1/3-dose verteporfin PDT may be an alternative method to treat the subacute CSC.
